Liver Disease Therapeutic Market Analysis Forecast Report 2024-2032

Global Liver Disease Therapeutic Market Analysis

The Global Liver Disease Therapeutic Market is experiencing steady growth and is projected to reach US$ 28.98 billion by 2032, up from US$ 13.86 billion in 2023. This growth represents a CAGR of 8.54% from 2024 to 2032, highlighting the increasing demand and potential in the field of liver disease treatment.

The liver is a crucial organ that plays a vital role in overall health. It is possible to target the liver effectively using genetic strategies with high liver tropism, including gene addition/editing and silencing, to address a wide range of diseases. Through gene addition and editing techniques, promising results have been observed in clinical trials, showing potential in overcoming challenges related to immune response and long-term stability. In addition, mRNA therapy has emerged as an innovative approach with demonstrated potential in treating liver-related disorders. The use of siRNAs and antisense oligonucleotides for gene silencing, specifically targeting hepatocytes, has paved the way for siRNA-based treatments for liver disorders. Furthermore, enzyme substitution therapy holds promise for mutations resulting in loss of function.

 

Request a free sample copy of the report: https://www.renub.com/liver-disease-market-p.php

 

Growth driver of the Global Liver Disease Therapeutic Market

 

• Rising prevalence of the liver disease

Liver disease treatment is growing due to the increasing incidence of diseases such as cancer, hepatitis, autoimmune diseases, and nonalcoholic fatty liver diseases. The aging population is contributing to the rising number of liver disease patients due to waning immunity with age. Government healthcare expenditures are increasing to make treatments affordable and accessible. A research study highlighted that chronic liver disease affects about 1.5 billion people globally and is a leading cause of death and illness worldwide. The most prevalent liver diseases are nonalcoholic fatty liver disease (NAFLD), hepatitis B, hepatitis C, and alcoholic liver disease. The global prevalence of nonalcoholic fatty liver disease (NAFLD) is predicted to reach 55.7% by 2040, which will lead to growth in the market for liver disease treatments.

 

• Growing health awareness worldwide

The prevalence of liver diseases is on the rise, emphasizing the crucial role of government and non-profit organizations in raising awareness on a global scale. Notably, the efforts of organizations like the International Liver Transplantation Society (ILTS), the International Living Donor Liver Transplantation Study Group (iLDLT), and the Liver Transplant Society of India (LTSI) are commendable in their initiatives to promote awareness of liver-related diseases. These organizations have been actively involved in supporting research and development aimed at preventing, treating, and curing liver diseases. One significant event was Asia’s first consensus conference on caring for patients who receive small liver grafts, which was recently held in India.

 

• The prevalence of excessive alcohol consumption and unhealthy diets has increased

The prevalence of excessive alcohol consumption and unhealthy diets has significantly increased, posing serious public health concerns. These behaviors contribute to a rise in chronic diseases such as obesity, heart disease, liver disease, and diabetes. Poor dietary choices, often high in processed foods and sugars, combined with heavy drinking, strain healthcare systems and reduce overall quality of life. Efforts to combat these trends include public health campaigns promoting healthy eating and responsible drinking, as well as policy measures to regulate advertising and availability of unhealthy food and alcoholic beverages. Addressing these issues is critical for improving long-term health outcomes.

 

North America Liver Disease Therapeutics Market

The North American region stands out as the leading market for clinical trial studies, largely because of the significant presence of research and academic institutions. Moreover, shifts in lifestyle patterns, including escalated alcohol consumption and unhealthy eating habits, have resulted in a higher incidence of liver disease. Looking ahead, the regional market is anticipated to experience growth, driven by increasing patient consciousness about their health and the introduction of new products aimed at fulfilling unmet medical needs. The incidence of liver diseases has increased in the United States, primarily due to high alcohol consumption. This has led to a rise in the burden of liver diseases, creating opportunities in the market for addressing unmet needs in disease management. Companies like Altimmune, Inc. and Madrigal Pharmaceuticals, Inc. have announced positive results from their trials of Pemvidutide and Resmetirom, respectively, showing potential for addressing non-alcoholic fatty liver disease.

 

Liver Disease Therapeutics Company Analysis

The major players include Abbott Laboratories, Astellas Pharma Inc, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Sanofi S.A, Pfizer Inc., and Takeda Pharmaceuticals.

 

Therapy Type

1. Anti-Rejection Drugs/Immunosuppressants
2. Chemotherapy Drugs
3. Targeted therapy
4. Vaccines
5. Immunoglobulins
6. Corticosteroids
7. Anti-Viral Drugs

 

Disease Type

1. Non-alcoholic Fatty Liver Disease (NAFLD)
2. Viral Hepatitis (B, C, D)
3. Alcoholic Liver Disease (ALD)
4. Autoimmune Liver Disease (ALD)

 

 

End Users

1. Hospitals
2. Laboratories
3. Others

 

 

Countries – Market has been covered from five Region viewpoints:

1. North America

 

1.1    United States

1.2    Canada

 

2    Europe

 

2.1    France

2.2    Germany

2.3    Italy

2.4    Spain

2.5    United Kingdom

2.6    Belgium

2.7    Netherlands

2    Turkey

 

3. Asia Pacific

 

3.1    China

3.2    Japan

3.3    India

3.4    South Korea

3.5    Thailand

3.6    Malaysia

3.7    Indonesia

3.8    Australia

3.9    New Zealand

 

4. Latin America

 

4.1    Brazil

4.2    Mexico

4.3    Argentina

 

5. Middle East & Africa

 

5.1    Saudi Arabia

5.2    UAE

5.3    South Africa

 

 

Company Analysis

1. Abbott Laboratories
2. Astellas Pharma Inc.
3. Bristol-Mayers Squibb
4. Gilead Sciences
5. GlaxoSmithKline Pharmaceuticals Ltd
6. F. Hoffmann-La Roche Ltd
7. Merck & Co. Inc
8. Novartis AG
9. Sanofi S.A
10. Pfizer Inc.
11. Takeda Pharmaceuticals

 

 

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Website: https://www.renub.com/